Genetic Testing in Cystic Kidney Disease
Kidney360 · 2026-08 · 7 (8) · 1909-1914
DOI: 10.34067/kid.0000001127 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Kidney360, online erschienen am 02.01.2026. Verfasst von Jacqueline Soraru und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology and Renal Transplantation, Fiona Stanley Hospital, Perth, Western Australia, Australia. Hauptthemen laut MEDLINE: Genetic Testing, Polycystic Kidney, Autosomal Dominant, Kidney Diseases, Cystic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NSW Ministry of Health.
Abstract (Originalsprache)
Genomic investigation is playing an increasing role in the management of cystic kidney diseases, reflecting a broader shift toward precision medicine in nephrology. Recent updates to the Kidney Disease Improving Global Outcomes Clinical Practice Guideline emphasize diagnostic genomics as a core component of autosomal dominant polycystic kidney disease care in particular, recognizing its utility across a range of clinical scenarios. Traditionally, diagnosis of autosomal dominant polycystic kidney disease has been clinical, using age-dependent imaging criteria for at-risk individuals via ultrasound and magnetic resonance imaging. Although these imaging modalities have good sensitivity, there are pitfalls in clinical diagnosis, particularly in patients with atypical clinical features, those without family history, or those at a young age. A confirmed genetic diagnosis can guide screening of at-risk family members, inform reproductive decisions, support safe selection of living related kidney donors, and provide the opportunity to use genotype-specific prognostication tools. In addition, as genotype-specific therapies enter the landscape, accurate genotyping will become essential for identifying which patients will benefit from treatment. This narrative review aims to provide a practical approach for the general nephrologist of when to offer genetic testing to patients with cystic kidney disease and outline the technical and genetic counseling considerations in the provision of patient-centered genetic investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Nephrology and Renal Transplantation, Fiona Stanley Hospital, Perth, Western Australia, Australia.
- Department of Nephrology and Hypertension, Perth Children's Hospital, Perth, Western Australia, Australia.
- Department of Nephrology, Townsville University Hospital, Townsville, Queensland, Australia.
- College of Medicine and Dentistry, James Cook University, Townsville, Queensland, Australia.
- Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland, Australia.
- Faculty of Medicine and Health, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.
ORCID-Profile: Jacqueline Soraru, Andrew J Mallett, Hugh J McCarthy, Amali Mallawaarachchi
Förderung
- NSW Ministry of Health
Zitieren
APA
Soraru, J., Mallett, A. J., McCarthy, H. J., & Mallawaarachchi, A. (2026). Genetic Testing in Cystic Kidney Disease. Kidney360, 7(8), 1909-1914. https://doi.org/10.34067/kid.0000001127
Vancouver
Soraru J, Mallett AJ, McCarthy HJ, Mallawaarachchi A. Genetic Testing in Cystic Kidney Disease. Kidney360. 2026;7(8):1909-1914. doi:10.34067/kid.0000001127
BibTeX
@article{Soraru2026,
author = {Soraru, Jacqueline and Mallett, Andrew J and McCarthy, Hugh J and Mallawaarachchi, Amali},
title = {Genetic Testing in Cystic Kidney Disease},
journal = {Kidney360},
year = {2026},
volume = {7},
number = {8},
pages = {1909--1914},
doi = {10.34067/kid.0000001127}
}
EUVIMED